XML 22 R12.htm IDEA: XBRL DOCUMENT v3.6.0.2
Note G - Segment Information
6 Months Ended
Dec. 31, 2016
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]
G. Segment Information
 
Our business consists of
two
segments for financial reporting purposes, identified as (i) private label contract manufacturing, which primarily relates to the provision of private label contract manufacturing services to companies that market and distribu
te nutritional supplements and other health care products; and (ii) patent and trademark licensing, which primarily includes direct raw material sales and royalty income from our license and supply agreements associated with the sale and use of beta-alanine under our CarnoSyn® trade name.
 
We evaluate performance based on a number of factors. The primary performance measures for each segment are net sales and income or loss from operations before corporate allocations. Operating income or loss for each segm
ent does not include corporate general and administrative expenses, interest expense and other miscellaneous income and expense items. Corporate general and administrative expenses include, but are not limited to: human resources, corporate legal, finance, information technology, and other corporate level related expenses, which are not allocated to any segment. The accounting policies of our segments are the same as those described in Note A above and in the consolidated financial statements included in our
2016
Annual Report.
 
Our operating results by business segment were as follows (in thousands):
 
   
Three Months Ended December 31,
   
Six Months Ended December 31,
 
 
 
2016
   
2015
   
2016
   
2015
 
Net Sales
                               
Private label contract manufacturing
  $
23,864
    $
21,619
    $
51,243
    $
37,884
 
Patent and trademark licensing
   
6,695
     
5,292
     
13,383
     
10,612
 
Total Net Sales
  $
30,559
    $
26,911
    $
64,626
    $
48,496
 
 
 
   
Three Months Ended December 31,
   
Six Months Ended December 31,
 
   
2016
   
2015
   
2016
   
2015
 
Income from Operations
                               
Private label contract manufacturing
  $
2,148
    $
2,543
    $
5,462
    $
4,603
 
Patent and trademark licensing
   
2,340
     
1,692
     
4,240
     
2,691
 
Income from operations of reportable segments
   
4,488
     
4,235
     
9,702
     
7,294
 
Corporate expenses not allocated to segments
   
(1,375
)    
(1,500
)    
(3,053
)    
(2,831
)
Total Income from Operations
  $
3,113
    $
2,735
    $
6,649
    $
4,463
 
 
 
 
Total Assets
 
December 31,
20
16
   
June 30,
2016
 
Private label contract manufacturing
  $
62,742
    $
66,375
 
Patent and Trademark Licensing
   
10,052
     
7,800
 
Total
  $
72,794
    $
74,175
 
 
Our private label contract manufacturing products are sold both in the U.S. and in markets outside the U.S., including Europe, Australia, Asia, Canada, Mexico and South Africa. Our primary market outside the U.S. is Europe. Our patent and trademark licensi
ng activities are primarily based in the U.S.
 
Net sales by geographic region, based on the customers
’ location, were as follows (in thousands):
 
   
Three Months Ended December 31,
   
Six Months Ended December 31,
 
 
 
2016
   
2015
   
2016
   
2015
 
                                 
United States
  $
13,654
    $
12,498
    $
28,879
    $
25,291
 
Markets outside of the United States
   
16,905
     
14,413
     
35,747
     
23,205
 
Total
  $
30,559
    $
26,911
    $
64,626
    $
48,496
 
 
 
Products manufactured by NAIE accounted for
60%
of net sales in markets outside the U.S. for the
three
months ended
December
31,
2016,
and
53%
for the
six
months ended
December
31,
2016.
Products manufactured by NAIE accounted for
71%
of net sales in mark
ets outside the U.S. for the
three
months ended
December
31,
2015,
and
74%
for the
six
months ended
December
31,
2015.
No
products manufactured by NAIE were sold in the U.S. during the
three
or
six
months ended
December
31,
2016
and
2015.
 
Assets and capit
al expenditures by geographic region, based on the location of the company or subsidiary at which they were located or made, were as follows (in thousands):
 
   
Long-Lived Assets
   
Total Assets
   
Capital Expenditures
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Six Months Ended
 
   
December 31,
2016
   
June 30,
2016
   
December 31,
2016
   
June 30,
2016
   
December 31,
2016
   
December 31,
2015
 
United States
  $
10,897
    $
9,678
    $
46,424
    $
49,755
    $
1,812
    $
320
 
Europe
   
6,572
     
5,489
     
26,370
     
24,420
     
1,550
     
1,090
 
    $
17,469
    $
15,167
    $
72,794 
    $
74,175
    $
3,362
    $
1,410